Tutorials › Response-Adaptive Randomization › Diagnosing Apparent Power Gains In Adaptive Trials

Comparison With Fixed Randomization · Tutorial 103 of 501

Diagnosing Apparent Power Gains In Adaptive Trials

Learn a practical diagnostic framework for deciding whether an apparent adaptive-trial power gain is genuine, fairly compared, and supported by a calibrated analysis.

Intermediate 12 min read

What You'll Learn

  • Define power and type I error as operating characteristics of the complete trial design and analysis.
  • Match total sample size, outcome assumptions, significance level, and testing procedure before comparing power.
  • Use Monte Carlo uncertainty to interpret simulated rejection rates.
  • Distinguish differences in estimated effects from differences in power under the same true effect.
  • Quantify how variable arm sizes can affect a variance benchmark, and recognize when that benchmark is insufficient.
  • Identify when null simulations, sensitivity analyses, or a design-matched comparison are needed.

What an Apparent Power Gain Must Survive

A response-adaptive design may report more rejections than a fixed-randomization design in a simulation. That difference is not, by itself, evidence that adaptation improved power. The designs may have different total sample sizes, different type I error rates, different effect assumptions, or different variability in the numbers assigned to each arm. A valid comparison checks these features before interpreting the rejection rates.

The relevant quantity is power under a specified alternative: the probability that the complete design and its prespecified analysis reject \(H_0\) when that alternative is true. The phrase “complete design and analysis” matters. It includes the allocation rule, stopping and sample-size rules, outcome model, and test used to make the decision. In a simulation, power is estimated by repeatedly generating trials under the alternative and applying the same planned analysis to each trial.

Definition: For a specified alternative and trial design, power is \(P(\text{reject }H_0\mid H_a\text{ is true})\). The type I error rate is \(P(\text{reject }H_0\mid H_0\text{ is true})\). A comparison of power is interpretable only alongside the type I error rates and the conditions under which both designs were evaluated.

For a fair comparison, match the total sample size \(N\), outcome distribution and treatment effect, significance level \(\alpha\), analysis, and rules for missing outcomes or stopping. If the goal is to compare allocation rules, vary the allocation rule while holding those other features fixed. If a design intentionally changes more than allocation, the result compares the packages of design choices, not the allocation rule alone.

A Reference Calculation for Fixed Allocation

A simple calculation helps identify a sample-size mismatch. Suppose outcomes in two arms are independent and normally distributed, with common known standard deviation \(\sigma\), and the arm sample sizes \(n_A\) and \(n_B\) are fixed. Let \(\delta=\mu_A-\mu_B\). For the difference in sample means, the standard error under this model is

$$ SE(\bar{x}_A-\bar{x}_B)=\sigma\sqrt{\frac{1}{n_A}+\frac{1}{n_B}}. $$

For a two-sided \(z\) test at level \(\alpha\), the test rejects when the absolute standardized difference exceeds \(z_{1-\alpha/2}\), the \(1-\alpha/2\) quantile of the standard normal distribution. Under a particular alternative \(\delta\), the standardized statistic has mean \(\lambda=\delta/SE\) and variance 1. Thus its power is

$$ P(Z<-z_{1-\alpha/2})+P(Z>z_{1-\alpha/2}) = \Phi(-z_{1-\alpha/2}-\lambda)+1-\Phi(z_{1-\alpha/2}-\lambda), \qquad Z\sim N(\lambda,1). $$

This is a reference calculation, not a formula that automatically gives the power of an outcome-adaptive trial. It assumes fixed arm sizes and the stated outcome and testing model. When the allocation depends on accrued outcomes, the arm sizes and outcomes can be related; the reference calculation may then fail to describe the actual test’s operating characteristics. Simulating the full adaptive process is often necessary.

Worked Example: A Larger Trial Can Look More Powerful

Consider a hypothetical continuous-outcome trial with \(\sigma=10\) outcome units, true difference \(\delta=4\) units, and a two-sided test at \(\alpha=0.05\). Compare two fixed, equal-allocation designs with total sample sizes 100 and 120. Assume independent normal outcomes, a common known standard deviation, complete follow-up, and the prespecified \(z\) test.

With \(N=100\), each arm has \(n_A=n_B=50\). Therefore

$$ SE=10\sqrt{\frac{1}{50}+\frac{1}{50}}=2.000, \qquad \lambda=\frac{4}{2.000}=2.000. $$

Using \(z_{0.975}=1.960\), the power is approximately

$$ \Phi(-1.960-2.000)+1-\Phi(1.960-2.000) = \Phi(-3.960)+1-\Phi(-0.040) \approx 0.516. $$

With \(N=120\), each arm has 60 participants, so

$$ SE=10\sqrt{\frac{1}{60}+\frac{1}{60}}=1.826, \qquad \lambda=\frac{4}{1.826}=2.191, $$

and the power is approximately

$$ \Phi(-1.960-2.191)+1-\Phi(1.960-2.191) \approx 0.591. $$

The larger trial has about 7.5 percentage points more power in this calculation. That difference cannot be credited to adaptive allocation: the comparison changed \(N\) from 100 to 120. A fair allocation comparison would use the same total sample size in both arms of the comparison.

Check Type I Error Before Comparing Power

Power estimates can mislead when one design rejects too often under the null. If an adaptive procedure has type I error above its target \(\alpha\), its higher rejection rate under an alternative may partly reflect a more permissive decision rule rather than a more efficient design. Conversely, a procedure with type I error below target may appear to have lower power because it is more conservative.

Estimate type I error by simulating trials under \(H_0\), running the full allocation and analysis procedures, and recording the proportion that reject. If \(R\) of \(M\) simulated trials reject, the estimated rate is \(\hat{p}=R/M\). Its approximate Monte Carlo standard error is \(\sqrt{\hat{p}(1-\hat{p})/M}\). This quantifies simulation noise; it does not repair a test whose operating characteristics are genuinely miscalibrated.

Worked Example: Is a Null Rejection Rate Consistent With Its Target?

Suppose two hypothetical designs are each evaluated in \(M=2{,}000\) simulated trials under the null, with target \(\alpha=0.05\). The fixed design rejects in 76 trials and the adaptive design in 132 trials. Assume both simulations use the same null outcome model, trial size, significance level, and planned analysis, and both run the entire allocation algorithm.

The estimated type I error rates are

$$ \hat{p}_{\mathrm{fixed}}=\frac{76}{2000}=0.0380, \qquad \hat{p}_{\mathrm{adaptive}}=\frac{132}{2000}=0.0660. $$

At a rate near 0.05, the approximate Monte Carlo standard error with 2,000 trials is

$$ \sqrt{\frac{0.05(1-0.05)}{2000}}=0.00487. $$

The estimated rates differ from the 0.05 target in opposite directions; the adaptive estimate is also noticeably higher than the fixed estimate. These results warrant investigation, but the Monte Carlo standard error is not a formal test that establishes why the difference occurred. Increase the number of simulations and examine whether the adaptive analysis is calibrated under the null before making a power claim. If the adaptive type I error remains elevated, its rejection rate under an alternative is not a like-for-like power comparison at the intended error level.

Separate Effect Estimates From Rejection Rates

Power is the probability of rejection at a specified true effect; it is not the size of the estimated effect. Designs can yield different distributions of effect estimates even when evaluated under the same true \(\delta\). An outcome-dependent allocation can also make an estimator’s behavior differ from the fixed-design case, so the analysis and estimator must be appropriate for the allocation mechanism. The earlier material on estimator bias and bias–variance distinctions is directly relevant here.

A useful diagnostic is to report, for each design, the mean estimated treatment difference across all simulated trials, its variability, and the rejection rate. Do not report only the estimates from trials that rejected: selecting on statistical significance tends to select extreme estimates. Nor should a simulation give one design a larger assumed effect than the other and then attribute the resulting rejection difference to allocation.

Worked Example: A Larger Estimate Among Significant Trials Is Not a Power Gain

Suppose a hypothetical simulation uses the same true treatment difference of 4 units and the same total sample size for each design. Across 1,000 trials per design, the mean estimated difference across all trials is 4.1 units for the adaptive design and 4.0 units for fixed randomization. Among only the trials that reject, the respective mean estimates are 7.2 and 7.0 units. Assume the same outcome scale, two-sided \(\alpha=0.05\), and a prespecified analysis for each design.

The all-trial averages differ by \(4.1-4.0=0.1\) unit. This is a small observed difference in this simulation, not evidence by itself that the adaptive estimator has a meaningful bias; its Monte Carlo uncertainty and sampling distribution would also need to be assessed. The rejection-only averages differ by \(7.2-7.0=0.2\) unit, but these summaries condition on passing a significance threshold. They describe selected estimates, not the estimators’ typical behavior across trials.

To compare power, count rejections among all 1,000 simulated trials under the common true effect. To diagnose estimation, compare the estimates across all trials and assess their uncertainty and bias relative to 4 units. The two questions are related but not interchangeable.

Allocation Variability and a Variance Benchmark

Even with the same total \(N\), an adaptive design may produce variable arm sizes. Under the fixed-count, independent, common-variance model, the variance of the difference in means is \(\sigma^2(1/n_A+1/n_B)\). This gives a useful benchmark for asking whether allocation imbalance could offset a potential benefit. It does not, on its own, calculate unconditional adaptive-trial power.

For a fixed total \(N\), write \(n_B=N-n_A\) and define \(f(n_A)=1/n_A+1/(N-n_A)\). On \(0<n_A<N\),

$$ f''(n_A)=\frac{2}{n_A^3}+\frac{2}{(N-n_A)^3}>0. $$

Thus \(f\) is convex, and Jensen’s inequality gives \(E[f(n_A)]\geq f(E[n_A])\). In this variance benchmark, variability in allocation counts increases the expected variance factor relative to using the mean allocation count. The argument requires valid arm counts and applies to the stated function; it does not account for outcome-dependent selection, estimator bias, or the full distribution of a test statistic. Those features require design-specific evaluation.

Worked Example: Same Mean Allocation, Different Allocation Variability

Consider a hypothetical trial with \(N=100\), equal outcome variances \(\sigma^2=100\) square units, and an adaptive allocation that yields \(n_A=20,30,40,50,60,70,80\) with respective probabilities \(0.10,0.10,0.15,0.30,0.15,0.10,0.10\). Assume, for this variance benchmark only, that the allocation counts are independent of the outcome noise and that the difference in means is unbiased conditional on the counts.

The probabilities sum to 1, and symmetry around 50 gives \(E[n_A]=50\). The variance factor at equal allocation is \(1/50+1/50=0.0400\), so the variance benchmark is \(100(0.0400)=4.000\) square units.

For the variable allocation, the expected factor is

$$ \begin{aligned} E\left[\frac{1}{n_A}+\frac{1}{100-n_A}\right] &=0.20(0.06250)+0.20(0.04762)\\ &\quad+0.30(0.04167)+0.30(0.04000)\\ &=0.04652. \end{aligned} $$

The corresponding expected variance benchmark is \(100(0.04652)=4.652\) square units, greater than 4.000. Its square root, about 2.157 units, is a summary of the square root of this expected variance, not the exact unconditional standard error of every adaptive estimator. Because the example assumes allocation independent of outcome noise, it illustrates allocation variability alone. If allocation responds to outcomes, this calculation is not a substitute for simulating the complete trial and its analysis.

A Practical Diagnostic Sequence

A useful comparison proceeds in an order that can expose misleading gains before they are interpreted. Use the same null and alternative models for each design, and preserve the planned allocation and analysis rules in every simulated replicate.

1
Align the comparison.
Check that \(N\), outcome assumptions, true effects, \(\alpha\), stopping rules, missing-data rules, and analysis are matched. If one differs, state that the comparison is of different design packages.
2
Calibrate under the null.
Estimate type I error for both designs with the full trial procedure. Investigate departures from the target before treating an alternative rejection rate as a fair power comparison.
3
Compare estimates and allocation counts.
Summarize estimates across all trials, their variability, and the distribution of \(n_A\) and \(n_B\). Distinguish estimation behavior from the rejection indicator.
4
Quantify simulation precision.
Report the number of simulated trials and Monte Carlo standard errors for rejection rates. Increase simulation replicates if the apparent difference is comparable to simulation noise.
5
Check robustness.
Repeat the matched comparison over scientifically plausible effects and outcome models. A gain that appears only under one fragile assumption should be described as assumption-dependent.

The main alternative to full design simulation is an analytic power calculation under a fixed-allocation model. It is valuable as a benchmark when its assumptions hold, but it does not represent outcome-dependent allocation automatically. Conditional power, which conditions on information available at a particular point in a trial, answers a different question from unconditional power across repetitions of the complete design. For adaptive-versus-fixed comparisons, unconditional simulation is often the clearest approach because it includes variation in allocation and outcomes together.

Common Mistakes and Limits

  • Attributing a gain when total sample sizes differ. More observations can increase power. Match \(N\) or clearly identify sample size as part of the design contrast.
  • Comparing rejection rates without checking the null. A higher type I error can inflate apparent power. Estimate both designs’ null rejection rates using the same target \(\alpha\).
  • Changing the assumed treatment effect. Power depends on the alternative. Use the same true effect for both designs, then examine sensitivity to other plausible effects separately.
  • Using only significant estimates. Rejection-selected estimates are not representative of estimates across all trials. Report all-trial summaries for estimation diagnostics.
  • Treating a variance benchmark as the adaptive trial’s exact power. Variable, outcome-dependent counts can affect the joint behavior of assignment and outcomes. Simulate the actual allocation and planned analysis when the fixed-count assumptions do not hold.
  • Overinterpreting simulation noise. A small difference in rejection rates may result from finite simulation replicates. Report the number of replicates and Monte Carlo uncertainty.

These checks diagnose a power claim; they do not establish that one allocation rule is universally preferable. The result remains conditional on the chosen outcome model, effect assumptions, estimator, test, and trial constraints. In particular, a design comparison should not be generalized beyond the scenarios evaluated without additional sensitivity analysis.

Key takeaway: An apparent power gain is credible only after a like-for-like comparison: matched sample size and assumptions, acceptable type I error, appropriate analysis, interpretable effect-estimate behavior, and adequate simulation precision. Allocation variability is a diagnostic, not a stand-alone verdict on an adaptive design.

Check Your Understanding

Answer each question, then compare your reasoning with the solutions below.

  1. Two designs use the same analysis, but one has 150 participants and the other has 120. Can a higher rejection rate establish a benefit from adaptive allocation? What should be checked?
  2. In 1,000 null simulations, an adaptive design rejects 68 times. Calculate its estimated type I error rate and approximate Monte Carlo standard error using the estimate.
  3. Why is the mean treatment-effect estimate among significant trials not a suitable summary of estimator bias?
  4. For fixed \(N\), why can variation in \(n_A\) increase the expected variance factor \(1/n_A+1/(N-n_A)\) relative to evaluating it at \(E[n_A]\)?

Solutions. (1) No. The total sample sizes differ, so the higher rejection rate may reflect the 30 additional participants. Match \(N\), effect and outcome assumptions, significance level, and analysis, or state that the comparison changes both sample size and allocation. Also check type I error. (2) The estimate is \(68/1000=0.0680\). Its approximate Monte Carlo standard error is \(\sqrt{0.0680(1-0.0680)/1000}=0.00796\). This describes simulation uncertainty, not whether the test is calibrated. (3) The summary conditions on crossing the rejection threshold, which selects unusually large or otherwise extreme estimates. Assess estimates over all simulated trials and compare their average with the true effect. (4) The function \(f(n_A)=1/n_A+1/(N-n_A)\) is convex because \(f''(n_A)=2/n_A^3+2/(N-n_A)^3>0\). Jensen’s inequality therefore gives \(E[f(n_A)]\geq f(E[n_A])\), under the benchmark’s valid-count assumptions. This alone does not give exact power for outcome-adaptive assignment.

Clinical Biostats